Navidea Biopharmaceuticals (NAVB) 10-Q 8 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 01, 2019
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000810509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		18,079,406
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,841,498	$ 3,475,881
Available-for-sale securities		799,270
Accounts and other receivables	145,816	21,151
Prepaid expenses and other	247,001	1,299,454
Total current assets	3,234,315	5,595,756
Property and equipment	1,206,280	1,251,185
Less accumulated depreciation and amortization	1,159,708	1,089,013
Property and equipment, net	46,572	162,172
Right-of-use lease assets	397,783
Less accumulated amortization	91,689
Right-of-use lease assets, net	306,094
License agreements, patents and trademarks	480,404	480,404
Less accumulated amortization	74,160	51,912
License agreements, patents and trademarks, net	406,244	428,492
Other assets	828,431	835,107
Total assets	4,821,656	7,021,527
Current liabilities:
Accounts payable	838,968	424,718
Accrued liabilities and other	2,487,752	2,517,047
Notes payable	0	316,074
Lease liabilities, current	249,615
Terminated lease liability, current		120,679
Total current liabilities	3,576,335	3,378,518
Lease liabilities	575,064
Terminated lease liability		468,494
Deferred revenue	700,000	700,000
Other liabilities	63,000	64,055
Total liabilities	4,914,399	4,611,067
Commitments and contingencies (Note 11)
Stockholders’ (deficit) equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2019 and December 31, 2018
Common stock; $.001 par value; 300,000,000 shares authorized; 18,059,406 and 10,019,535 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	209,056	200,391
Additional paid-in capital	343,929,129	338,265,383
Accumulated deficit	(344,899,232)	(336,722,905)
Accumulated other comprehensive loss		(730)
Total Navidea stockholders' (deficit) equity	(761,047)	1,742,139
Noncontrolling interest	668,304	668,321
Total stockholders’ (deficit) equity	(92,743)	2,410,460
Total liabilities and stockholders’ (deficit) equity	$ 4,821,656	$ 7,021,527

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	18,059,406	10,019,535
Common stock, shares outstanding (in shares)	18,059,406	10,019,535

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Revenue from contract with customer		$ 5,000	$ 22,000	$ 35,000	$ 303,000
Grant and other revenue		231,916	209,146	514,589	762,549
Revenues, Total		236,811	231,458	538,527	1,050,030
Cost of revenue		195	38,101	6,559	73,811
Gross profit		236,616	193,357	531,968	976,219
Operating expenses:
Research and development		1,801,558	1,225,770	3,612,783	3,367,444
Selling, general and administrative		1,519,496	2,688,703	5,109,612	6,254,474
Total operating expenses		3,321,054	3,914,473	8,722,395	9,621,918
Loss from operations	[1]	(3,084,438)	(3,721,116)	(8,190,427)	(8,645,699)
Other income (expense):
Interest income (expense), net		11,858	(28,074)	23,336	(20,234)
Loss on extinguishment of debt					(4,265,434)
Other, net		(1,524)	3,540	(5,880)	1,654
Total other income (expense), net	[2]	10,334	(24,534)	17,456	(4,284,014)
Loss before income taxes		(3,074,104)	(3,745,650)	(8,172,971)	(12,929,713)
Provision for income taxes			(76,259)	(707)	(65,330)
Loss from continuing operations		(3,074,104)	(3,821,909)	(8,173,678)	(12,995,043)
Loss from discontinued operations				(2,665)	(1,938)
Gain on sale					43,053
Net loss		(3,074,104)	(3,821,909)	(8,176,343)	(12,953,928)
Less loss attributable to noncontrolling interest		(2)	(308)	(16)	(333)
Net loss attributable to common stockholders		$ (3,074,102)	$ (3,821,601)	$ (8,176,327)	$ (12,953,595)
Loss per common share (basic and diluted):
Continuing operations (in dollars per share)		$ (0.17)	$ (0.46)	$ (0.62)	$ (1.59)
Discontinued operations (in dollars per share)					0.01
Attributable to common stockholders (in dollars per share)		$ (0.17)	$ (0.46)	$ (0.62)	$ (1.58)
Weighted average shares outstanding (in shares)		18,044,406	8,342,771	13,082,393	8,198,197
Royalty [Member]
Revenue:
Revenue from contract with customer		$ 4,895	$ 2,382	$ 13,985	$ 9,842
License [Member]
Revenue:
Revenue from contract with customer			$ 19,930	$ 9,953	$ 277,639
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Net (loss) income	$ (3,074,104)	$ (2,673,179)	$ (2,429,061)	$ (3,821,909)	$ (2,394,057)	$ (6,737,962)	$ (8,176,343)	$ (12,953,928)
Unrealized (loss) gain on available-for-sale securities	(188)	(40)	958	1,012	508	(176)	730	1,344
Comprehensive loss	$ (3,074,292)	$ (2,673,219)	$ (2,428,103)	$ (3,820,897)	$ (2,393,549)	$ (6,738,138)	$ (8,175,613)	$ (12,952,584)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Underwritten Public Offering [Member]Common Stock [Member]	Underwritten Public Offering [Member]Additional Paid-in Capital [Member]	Underwritten Public Offering [Member]Retained Earnings [Member]	Underwritten Public Offering [Member]AOCI Attributable to Parent [Member]	Underwritten Public Offering [Member]Noncontrolling Interest [Member]	Underwritten Public Offering [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]Noncontrolling Interest [Member]	Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017													8,110,332
Balance at Dec. 31, 2017													$ 162,207	$ 331,128,787	$ (319,908,968)	$ (2,396)	$ 668,700	$ 12,048,330
Issued restricted stock (in shares)													10,000
Issued restricted stock													$ 200					200
Stock compensation expense														137,964				137,964
Net income (loss)															(6,737,953)		(9)	(6,737,962)
Unrealized (loss) gain on available-for-sale securities																(176)		(176)
Total comprehensive loss																		(6,738,138)
Issued stock to 401(k) plan (in shares)													4,734
Issued stock to 401(k) plan													$ 95	35,885				35,980
Impact of adoption of ASC Topic 606 at Dec. 31, 2017															(700,000)			(700,000)
Issued stock in payment of employee bonuses (in shares)													22,920
Issued stock in payment of employee bonuses													$ 458	164,563				165,021
Balance (in shares) at Mar. 31, 2018													8,147,986
Balance at Mar. 31, 2018													$ 162,960	331,467,199	(327,346,921)	(2,572)	668,691	4,949,357
Balance (in shares) at Dec. 31, 2017													8,110,332
Balance at Dec. 31, 2017													$ 162,207	331,128,787	(319,908,968)	(2,396)	668,700	12,048,330
Net income (loss)																		(12,953,928)
Unrealized (loss) gain on available-for-sale securities																		1,344
Total comprehensive loss																		$ (12,952,584)
Issued stock to 401(k) plan (in shares)																		4,734
Issued stock to 401(k) plan																		$ 36,000
Impact of adoption of ASC Topic 606 at Dec. 31, 2017															(700,000)			$ (700,000)
Issued stock in payment of employee bonuses (in shares)																		55,938
Issued stock in payment of employee bonuses																		$ 317,000
Balance (in shares) at Sep. 30, 2018													9,094,535
Balance at Sep. 30, 2018													$ 181,891	334,723,420	(333,562,563)	(1,052)	668,367	2,010,063
Balance (in shares) at Mar. 31, 2018													8,147,986
Balance at Mar. 31, 2018													$ 162,960	331,467,199	(327,346,921)	(2,572)	668,691	4,949,357
Stock compensation expense														79,183				79,183
Net income (loss)															(2,394,041)		(16)	(2,394,057)
Unrealized (loss) gain on available-for-sale securities																508		508
Total comprehensive loss																		(2,393,549)
Issued stock in payment of employee bonuses (in shares)													33,018
Issued stock in payment of employee bonuses													$ 660	151,221				151,881
Balance (in shares) at Jun. 30, 2018													8,181,004
Balance at Jun. 30, 2018													$ 163,620	331,697,603	(329,740,962)	(2,064)	668,675	2,786,872
Stock Issued (in shares)							916,031
Stock Issued							$ 18,321	$ 2,981,679				$ 3,000,000
Stock compensation expense														44,088				44,088
Net income (loss)															(3,821,601)		(308)	(3,821,909)
Unrealized (loss) gain on available-for-sale securities																1,012		1,012
Total comprehensive loss																		(3,820,897)
Cancelled forfeited restricted stock (in shares)													(2,500)
Cancelled forfeited restricted stock													$ (50)	(50)
Balance (in shares) at Sep. 30, 2018													9,094,535
Balance at Sep. 30, 2018													$ 181,891	334,723,420	(333,562,563)	(1,052)	668,367	2,010,063
Balance (in shares) at Dec. 31, 2018													10,019,535
Balance at Dec. 31, 2018													$ 200,391	338,265,383	(336,722,905)	(730)	668,321	2,410,460
Issued restricted stock (in shares)													15,000
Issued restricted stock													$ 300					300
Stock Issued (in shares)													17,857
Stock Issued													$ 357	49,643				50,000
Stock compensation expense														61,978				61,978
Net income (loss)															(2,429,049)		(12)	(2,429,061)
Unrealized (loss) gain on available-for-sale securities																958		958
Total comprehensive loss																		(2,428,103)
Balance (in shares) at Mar. 31, 2019													10,052,392
Balance at Mar. 31, 2019													$ 201,048	338,377,004	(339,151,954)	228	668,309	94,635
Balance (in shares) at Dec. 31, 2018													10,019,535
Balance at Dec. 31, 2018													$ 200,391	338,265,383	(336,722,905)	(730)	668,321	2,410,460
Net income (loss)																		(8,176,343)
Unrealized (loss) gain on available-for-sale securities																		730
Total comprehensive loss																		$ (8,175,613)
Issued stock to 401(k) plan (in shares)																		8,128
Issued stock to 401(k) plan																		$ 20,000
Balance (in shares) at Sep. 30, 2019													18,059,406
Balance at Sep. 30, 2019													$ 209,056	343,929,129	(344,899,232)		668,304	(92,743)
Balance (in shares) at Mar. 31, 2019													10,052,392
Balance at Mar. 31, 2019													$ 201,048	338,377,004	(339,151,954)	228	668,309	94,635
Stock Issued (in shares)													8,000,000
Stock Issued	$ 8,000	$ 5,158,441				$ 5,166,441
Stock compensation expense														66,159				66,159
Net income (loss)															(2,673,176)		(3)	(2,673,179)
Unrealized (loss) gain on available-for-sale securities																(40)		(40)
Total comprehensive loss																		(2,673,219)
Rounding adjustments related to reverse stock split (in shares)													(1,114)
Rounding adjustments related to reverse stock split														(3,385)				(3,385)
Issued stock to 401(k) plan (in shares)													8,128
Issued stock to 401(k) plan													$ 8	19,580				19,588
Value of warrants issued in connection with public offering														261,288				261,288
Balance (in shares) at Jun. 30, 2019													18,059,406
Balance at Jun. 30, 2019													$ 209,056	343,879,087	(341,825,130)	188	668,306	2,931,507
Stock compensation expense														50,042				50,042
Net income (loss)															(3,074,102)		(2)	(3,074,104)
Unrealized (loss) gain on available-for-sale securities																(188)		(188)
Total comprehensive loss																		(3,074,292)
Balance (in shares) at Sep. 30, 2019													18,059,406
Balance at Sep. 30, 2019													$ 209,056	$ 343,929,129	$ (344,899,232)		$ 668,304	$ (92,743)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)	3 Months Ended
	Jun. 30, 2019USD ($)
Underwritten Public Offering [Member] | Additional Paid-in Capital [Member]
Stock issued, net offering costs	$ 841,559

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net (loss) income	$ (8,176,343)	$ (12,953,928)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	107,794	113,088
Loss on disposal and abandonment of assets	1,672
Compounded interest on long term debt		128,902
Stock compensation expense	178,179	261,235
Loss on extinguishment of debt		4,265,434
Value of stock issued to employees		316,902
Value of stock issued to 401(k) plan for employer matching contributions	19,588	35,980
Changes in operating assets and liabilities:
Accounts and other receivables	(124,665)	12,860,320
Prepaid expenses and other assets	753,034	632,106
Accounts payable	414,250	(239,519)
Accrued and other liabilities	216,180	992,304
Deferred revenue	(11,024)	(10,037)
Net cash (used in) provided by operating activities	(6,621,335)	6,402,787
Cash flows from investing activities:
Purchases of available-for-sale securities		(200,000)
Proceeds from sales of available-for-sale securities	400,000	200,000
Maturities of available-for-sale securities	400,000	1,000,000
Proceeds from disposal (payments for purchases) of equipment	28,382	(19,317)
Net cash provided by investing activities	828,382	980,683
Cash flows from financing activities:
Proceeds from issuance of common stock	6,046,915	3,000,200
Payment of common stock issuance costs	(572,271)
Payment of debt-related costs		(7,153,000)
Principal payments on notes payable	(316,074)	(318,211)
Net cash provided by (used in) financing activities	5,158,570	(4,471,011)
Net (decrease) increase in cash and cash equivalents	(634,383)	2,912,459
Cash and cash equivalents, beginning of period	3,475,881	2,795,006
Cash and cash equivalents, end of period	$ 2,841,498	$ 5,707,465

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: September 30, 2019 three nine September 30, 2019 2018 September 30, 2019 not December 31, 2018, 10 Our consolidated financial statements include the accounts of Navidea, our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, and our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. On April 26, 2019, one twenty $0.001 twenty one 201.0 10.1 not 300.0 $0.001 January 1, 2018. not b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: ( 2 Notes payable: December 31, 2018 December 31, 2018, $316,000, $316,000. not September 30, 2019. 9. ( 3 Derivative liabilities: $63,000 September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 4. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Recent ly Adopted Accounting Standards : February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 In July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. The Company adopted ASU 2016 02, 2018 10 2018 11 January 1, 2019 not 12 The adoption of ASU 2016 02 $407,000 January 1, 2019 2016 02 not 10. In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company’s Annual Report on Form 10 $4.1 11. The Company was also engaged in litigation with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P. (“PPVA”), Platinum Partners Capital Opportunity Fund (“PPCO”), Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”), in which Platinum-Montaur was seeking damages of approximately $1.9 October 2018, November 2018, September 5, 2019 9 11. In addition, the Company is engaged in litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Notes 7 11. On June 18, 2019, 8,000,000 June 13, 2019, $0.75 8,000,000 4,000,000 $0.75 4,000,000 $0.69375 $5,555,000. 2b 3 Tc99m In addition, the Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The June 2019 $5.5 twelve 10

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3 . Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight 10 The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three September 30, 2019 2018, $5,000 $22,000, nine September 30, 2019 2018, $35,000 $303,000, three nine September 30, 2019 2018, not The following tables disaggregate the Company’s revenue from contracts with customers for the three nine September 30, 2019 2018. T hree Months Ended September 30 , 2019 Diagnostics Royalty revenue: Europe $ 4,895 T hree Months Ended September 30 , 2018 Diagnostics Royalty revenue: Europe $ 2,382 License revenue: NAV4694 sublicense $ 14,930 Tc99m tilmanocept sublicense, China 5,000 Total $ 19,930 Nine Months Ended September 30, 2019 Diagnostics Royalty revenue: Europe $ 13,985 License revenue: NAV4694 sublicense $ 9,953 Other revenue: Additional stability studies $ 11,024 Nine Months Ended September 30 , 201 8 Diagnostics Royalty revenue: Europe $ 9,842 License revenue: NAV4694 sublicense $ 272,639 Tc99m tilmanocept sublicense, China 5,000 Total $ 277,639 Other revenue: Additional stability studies $ 15,037 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through September 30, 2019, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three nine September 30, 2019 2018. Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total deferred revenue, beginning of period $ 1,195,000 $ 721,024 $ 711,024 $ 26,061 Impact of adoption of ASU 2014-09 and related standards — — — 700,000 Revenue deferred related to sublicense — — 495,000 10,000 Refund of deferred revenue related to sublicense (495,000 ) — (495,000 ) — Revenue recognized from satisfaction of performance obligations — (5,000 ) (11,024 ) (20,037 ) Total deferred revenue, end of period $ 700,000 $ 716,024 $ 700,000 $ 716,024 The Company had trade receivables of approximately $0 $12,000 September 30, 2019 December 31, 2018. In addition to revenue from contracts from customers, we also generate revenue from NIH grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three September 30, 2019 2018, $232,000 $169,000, nine September 30, 2019 2018, $497,000 $680,000,

Note 4 - Fair Value

Note 4 - Fair Value	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4 . Fair Value The Company’s available-for-sale securities consist of certificates of deposit which are measured using Level 2 MT issued warrants to purchase MT common stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 September 30, 2019 December 31, 2018, The following tables set forth, by level, financial assets and liabilities measured at fair value on a recurring basis. Liabilities Measured at Fair Value on a Recurring Basis as of September 30 , 2019 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 a. Valuation Processes-Level 3 third b. Sensitivity Analysis-Level 3 may may not There were no 1 2 nine September 30, 2019 2018. 3 no 3 nine September 30, 2019 2018.

Note 5 - Stock-based Compensati

Note 5 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	5 . Stock-Based Compensation For the three September 30, 2019 2018, $50,000 $44,000, nine September 30, 2019 2018, $178,000 $261,000, not three nine September 30, 2019 2018. A summary of the status of our stock options as of September 30, 2019, nine Nine Months Ended September 30 , 201 9 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2019 157,915 $ 24.82 Granted 95,250 5.89 Exercised — — Canceled and Forfeited (5,304 ) 8.94 Expired (9,041 ) 31.21 Outstanding, September 30, 2019 238,820 $ 17.38 7.4 $ — Exercisable, September 30, 2019 80,157 $ 33.13 5.0 $ — A summary of the status of our unvested restricted stock as of September 30, 2019, nine Nine Months Ended September 30 , 201 9 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2019 5,000 $ 7.42 Granted 15,000 2.75 Vested (5,000 ) 7.42 Forfeited — — Unvested, September 30, 2019 15,000 $ 2.75 As of September 30, 2019, $83,000 0.9

Note 6 - Loss Per Share

Note 6 - Loss Per Share	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	6 . Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the nine September 30, 2019 2018 1,490,531 930,909 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 15,000 5,000 nine September 30, 2019 2018,

Note 7 - Investment in Macropha

Note 7 - Investment in Macrophage Therapeutics, Inc.	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	7 . Investment in Macrophage Therapeutics, Inc. In August 2018, 5% one 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, April 26, 2019, June 13, 2019, third July 5, 2019, not Also on February 20, 2019, June 12, 2019, not May 23, 2019 On July 26, 2019, 11.

Note 8 - Accounts Payable, Accr

Note 8 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	8. Accounts Payable , Accrued Liabilities and Other Accounts payable at September 30, 2019 $65,000 September 30, 2019 December 31, 2018 $317,000 $1.6

Note 9 - Notes Payable

Note 9 - Notes Payable	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	9 . Notes Payable Platinum-Montaur Life Sciences LLC In July 2012, $50 March 2017, $7.7 November 2018, 925,000 817,857 $3.2 $2.2 $1.0 11. During the nine September 30, 2018, $129,000 IPFS Corporation In November 2017, $396,000 4.0%. ten $40,000, August 2018. November 2018, $393,000 5.1%. ten $40,000, August 2019. Interest expense related to the IPFS notes payable totaled $6,000 $5,000 nine September 30, 2019 2018, $0 $316,000 September 30, 2019 December 31, 2018, Summary During the three September 30, 2019 2018, $1,000 $45,000, $0 $44,000 three September 30, 2019 2018, nine September 30, 2019 2018, $6,000 $134,000, $0 $129,000 nine September 30, 2019 2018,

Note 10 - Leases

Note 10 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. Leases We currently lease approximately 5,000 4995 June 2020 $3,000. 2,000 560 $3,000. March 31, 2019 not In addition, we currently lease approximately 25,000 5600 October 2022, $26,000 2019. June 2017, $39,000 October 2022. We also currently lease a vehicle. The lease term expires in September 2021, $300. We adopted ASU 2016 02, Leases (Topic 842 January 1, 2019. 2016 02 Operating Lease Right- of-Use Assets Operating Lease Liabilities Terminated Lease Liability Deferred Rent Pre-adoption balance $ — $ — $ 589,173 $ 2,587 Change 406,842 998,602 (589,173 ) (2,587 ) Post-adoption balance $ 406,842 $ 998,602 $ — $ — All of our leases are operating leases and are included in right-of-use lease assets, current lease liabilities and noncurrent lease liabilities on our consolidated balance sheets. These assets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term operating leases which have an initial term of 12 not Lease expense for operating leases is recognized on a straight-line basis over the lease term, and is included in selling, general and administrative expenses on our consolidated statements of operations. Total operating lease expense was $54,000 $176,000 three nine September 30, 2019, $94,000 $283,000 three nine September 30, 2019, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2019. Maturity of Lease Liabilities Operating Lease Payments 2019 (remaining) $ 90,324 2020 319,034 2021 306,781 2022 253,339 Total undiscounted operating lease payments 969,478 Less imputed interest 144,799 Present value of operating lease liabilities $ 824,679 Balance Sheet Classification Current lease liabilities $ 249,615 Noncurrent lease liabilities 575,064 Total operating lease liabilities $ 824,679 Other Information Weighted-average remaining lease term for operating leases (in years) 2.9 Weighted-average discount rate for operating leases 12.3 % An initial right-of-use lease asset of $407,000 2016 02. $249,000 nine September 30, 2019

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 1 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. CRG Litigation As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On April 9, 2018, $7.1 414, 414” $4.1 $59.0 The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”) related to Navidea’s claims that the Lenders fraudulently induced Navidea to enter into a settlement agreement and breached the terms of the same through certain actions taken by the Lenders in connection with the Global Settlement Agreement reached in 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 7, 2019, June 28, 2019. CRG filed another lawsuit in the Texas Court in April 2018. not $7.1 414 2. Platinum Li tigation In November 2017, $1.9 March 3, 2017, October 31, 2018, no On November 30, 2018, January 22, 2019, February 26, 2019, September 5, 2019 9. Goldberg Agreement and Litigation In August 2018, one 1,175,000 1,175,000 18 5% November 2018, 925,000 250,000 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, April 26, 2019, June 13, 2019, third July 5, 2019, not Also on February 20, 2019, June 12, 2019, not May 23, 2019 On July 26, 2019, 7. NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $4.0 three four $2.1 June 30, 2018, four five December 31, 2017. In addition, the Deficiency Letter stated that the Staff determined that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003 Navidea was required to submit a plan to the NYSE American by September 14, 2018 February 14, 2020. On October 25, 2018, not 1003 $6.0 five $2.1 June 30, 2018, five December 31, 2017. The Company is required to provide quarterly updates to the NYSE American staff (the “Staff”) concurrent with its interim/annual SEC filings. If Navidea fails to regain compliance with the stockholders’ equity standards by February 14, 2020, On April 2, 2019, not 1003 $2.0 two three 10 $1.7 December 31, 2018, five December 31, 2018. The NYSE Letter also required the Company to regain compliance with the price standard in order to be considered for continued trading through its equity plan period end date of February 14, 2020, one twenty April 26, 2019. On April 30, 2019, 1003 1003 1003 1003 February 14, 2020, In accordance with ASC Topic 450, Contingencies not

Note 12 - Equity

Note 12 - Equity	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 2 . Equity On March 22, 2019, $3.0 March 22, 2019 ( $50,000 $2.80, not June 15, 2019. No June 15, 2019 On June 18, 2019, 8,000,000 $0.75 8,000,000 4,000,000 $0.75 4,000,000 $0.69375 30 1,200,000 $0.69375. not The Company paid the Underwriter (a) a management fee equal to 1.0% $50,000 $100,000 $10,000 $5,555,000. 2b 3 Tc99m During the nine September 30, 2018, 55,938 $317,000 2017 During the nine September 30, 2019 2018, 8,128 4,734 401 $20,000 $36,000,

Note 13 - Stock Warrants

Note 13 - Stock Warrants	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 3 . Stock Warrants Pursuant to the Underwriting Agreement related to the June 18, 2019 600,000 7.5% five $0.9375 125% $261,000 88.6%, 1.8% $0. At September 30, 2019, 1.4 $0.20 $50.00 $13.46 one 15.9 In addition, at September 30, 2019, 300 $2,000

Note 14 - Income Taxes

Note 14 - Income Taxes	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 4 . Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not September 30, 2019 December 31, 2018, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not September 30, 2019 The Tax Cuts and Jobs Act was signed into law on December 22, 2017. 35% 21%, January 1, 2018. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. December 31, 2018, first 50% $1.2 $621,000 September 2019. $621,000 September 30, 2019. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no September 30, 2019 December 31, 2018 not twelve September 30, 2019, 2015 2018 As of September 30, 2019, $130.9 $20.3 $8.7

Note 15 - Segments

Note 15 - Segments	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 5 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two 99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended September 30 , 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 4,895 $ — $ — $ 4,895 Grant and other revenue 77,049 154,867 — 231,916 Total revenue 81,944 154,867 — 236,811 Cost of revenue 195 — — 195 Research and development expenses 1,678,423 123,135 — 1,801,558 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 1,052 1,484,155 1,485,207 Depreciation and amortization (2) — — 34,289 34,289 (Loss) income from operations (3) (1,596,674 ) 30,680 (1,518,444 ) (3,084,438 ) Other income (4) — — 10,334 10,334 Income tax (expense) benefit (72 ) 16 55 — Net (loss) income (1,596,746 ) 30,696 (1,508,055 ) (3,074,104 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Capital expenditures — — — — T hree Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,382 $ — $ — $ 2,382 License revenue 19,930 — — 19,930 Grant and other revenue 65,505 143,641 — 209,146 Total revenue 87,817 143,641 — 231,458 Cost of revenue 38,101 — — 38,101 Research and development expenses 711,355 514,415 — 1,225,770 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 20,532 2,630,581 2,651,113 Depreciation and amortization (2) — — 37,590 37,590 Loss from operations (3) (661,639 ) (391,306 ) (2,668,171 ) (3,721,116 ) Other expense (4) — — (24,534 ) (24,534 ) Income tax expense (10,081 ) (3,879 ) (62,299 ) (76,259 ) Net loss (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 16,152 16,152 Nine Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 13,985 $ — $ — $ 13,985 License revenue 9,953 — — 9,953 Grant and other revenue 309,670 204,919 — 514,589 Total revenue 333,608 204,919 — 538,527 Cost of revenue 6,559 — — 6,559 Research and development expenses 3,194,468 418,315 — 3,612,783 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 15,828 4,985,990 5,001,818 Depreciation and amortization (2) — — 107,794 107,794 Loss from operations (3) (2,867,419 ) (229,224 ) (5,093,784 ) (8,190,427 ) Other income (4) — — 17,456 17,456 Provision for income tax (248 ) (20 ) (439 ) (707 ) Net loss from continuing operations (2,867,667 ) (229,244 ) (5,076,767 ) (8,173,678 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (2,870,332 ) (229,244 ) (5,076,767 ) (8,176,343 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Capital expenditures — — — — Nine Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,842 $ — $ — $ 9,842 License revenue 277,639 — — 277,639 Grant and other revenue 454,830 307,719 — 762,549 Total revenue 742,311 307,719 — 1,050,030 Cost of revenue 73,811 — — 73,811 Research and development expenses 2,409,524 957,920 — 3,367,444 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 45,769 6,095,617 6,141,386 Depreciation and amortization (2) — — 113,088 113,088 Loss from operations (3) (1,741,024 ) (695,970 ) (6,208,705 ) (8,645,699 ) Other expense (4) — — (4,284,014 ) (4,284,014 ) Income tax expense (8,797 ) (3,517 ) (53,017 ) (65,330 ) Net loss from continuing operations (1,749,821 ) (699,487 ) (10,545,736 ) (12,995,043 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,708,706 ) (699,487 ) (10,545,736 ) (12,953,928 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 19,317 19,317 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 ) Depreciation and amortization is reflected in selling, general and administrative expenses ( $34,289 $37,590 three September 30, 2019 2018, $107,794 $113,088 nine September 30, 2019 2018, ( 3 ) Loss from operations does not ( 4 ) Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not

Note 16 - Supplemental Disclosu

Note 16 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 6 . Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2019 2018, $6,000 $8,000, nine September 30, 2019 2018, 8,128 4,734 401 $20,000 $36,000,

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	1 7 . Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2019 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: September 30, 2019 three nine September 30, 2019 2018 September 30, 2019 not December 31, 2018, 10 Our consolidated financial statements include the accounts of Navidea, our wholly owned subsidiary, Navidea Biopharmaceuticals Limited, and our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. On April 26, 2019, one twenty $0.001 twenty one 201.0 10.1 not 300.0 $0.001 January 1, 2018. not
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: ( 2 Notes payable: December 31, 2018 December 31, 2018, $316,000, $316,000. not September 30, 2019. 9. ( 3 Derivative liabilities: $63,000 September 30, 2019 December 31, 2018 September 30, 2019 December 31, 2018 4.
Revenue [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
New Accounting Pronouncements, Policy [Policy Text Block]	d. Recent ly Adopted Accounting Standards : February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 In July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. The Company adopted ASU 2016 02, 2018 10 2018 11 January 1, 2019 not 12 The adoption of ASU 2016 02 $407,000 January 1, 2019 2016 02 not 10. In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	T hree Months Ended September 30 , 2019 Diagnostics Royalty revenue: Europe $ 4,895 T hree Months Ended September 30 , 2018 Diagnostics Royalty revenue: Europe $ 2,382 License revenue: NAV4694 sublicense $ 14,930 Tc99m tilmanocept sublicense, China 5,000 Total $ 19,930 Nine Months Ended September 30, 2019 Diagnostics Royalty revenue: Europe $ 13,985 License revenue: NAV4694 sublicense $ 9,953 Other revenue: Additional stability studies $ 11,024 Nine Months Ended September 30 , 201 8 Diagnostics Royalty revenue: Europe $ 9,842 License revenue: NAV4694 sublicense $ 272,639 Tc99m tilmanocept sublicense, China 5,000 Total $ 277,639 Other revenue: Additional stability studies $ 15,037
Contract with Customer, Asset and Liability [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2019 2018 2019 2018 Total deferred revenue, beginning of period $ 1,195,000 $ 721,024 $ 711,024 $ 26,061 Impact of adoption of ASU 2014-09 and related standards — — — 700,000 Revenue deferred related to sublicense — — 495,000 10,000 Refund of deferred revenue related to sublicense (495,000 ) — (495,000 ) — Revenue recognized from satisfaction of performance obligations — (5,000 ) (11,024 ) (20,037 ) Total deferred revenue, end of period $ 700,000 $ 716,024 $ 700,000 $ 716,024

Note 4 - Fair Value (Tables)

Note 4 - Fair Value (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities Measured at Fair Value on a Recurring Basis as of September 30 , 2019 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000

Note 5 - Stock-based Compensa_2

Note 5 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30 , 201 9 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2019 157,915 $ 24.82 Granted 95,250 5.89 Exercised — — Canceled and Forfeited (5,304 ) 8.94 Expired (9,041 ) 31.21 Outstanding, September 30, 2019 238,820 $ 17.38 7.4 $ — Exercisable, September 30, 2019 80,157 $ 33.13 5.0 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30 , 201 9 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2019 5,000 $ 7.42 Granted 15,000 2.75 Vested (5,000 ) 7.42 Forfeited — — Unvested, September 30, 2019 15,000 $ 2.75

Note 10 - Leases (Tables)

Note 10 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Operating Lease Right- of-Use Assets Operating Lease Liabilities Terminated Lease Liability Deferred Rent Pre-adoption balance $ — $ — $ 589,173 $ 2,587 Change 406,842 998,602 (589,173 ) (2,587 ) Post-adoption balance $ 406,842 $ 998,602 $ — $ —
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2019 (remaining) $ 90,324 2020 319,034 2021 306,781 2022 253,339 Total undiscounted operating lease payments 969,478 Less imputed interest 144,799 Present value of operating lease liabilities $ 824,679 Balance Sheet Classification Current lease liabilities $ 249,615 Noncurrent lease liabilities 575,064 Total operating lease liabilities $ 824,679 Other Information Weighted-average remaining lease term for operating leases (in years) 2.9 Weighted-average discount rate for operating leases 12.3 %

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30 , 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 4,895 $ — $ — $ 4,895 Grant and other revenue 77,049 154,867 — 231,916 Total revenue 81,944 154,867 — 236,811 Cost of revenue 195 — — 195 Research and development expenses 1,678,423 123,135 — 1,801,558 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 1,052 1,484,155 1,485,207 Depreciation and amortization (2) — — 34,289 34,289 (Loss) income from operations (3) (1,596,674 ) 30,680 (1,518,444 ) (3,084,438 ) Other income (4) — — 10,334 10,334 Income tax (expense) benefit (72 ) 16 55 — Net (loss) income (1,596,746 ) 30,696 (1,508,055 ) (3,074,104 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Capital expenditures — — — — T hree Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,382 $ — $ — $ 2,382 License revenue 19,930 — — 19,930 Grant and other revenue 65,505 143,641 — 209,146 Total revenue 87,817 143,641 — 231,458 Cost of revenue 38,101 — — 38,101 Research and development expenses 711,355 514,415 — 1,225,770 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 20,532 2,630,581 2,651,113 Depreciation and amortization (2) — — 37,590 37,590 Loss from operations (3) (661,639 ) (391,306 ) (2,668,171 ) (3,721,116 ) Other expense (4) — — (24,534 ) (24,534 ) Income tax expense (10,081 ) (3,879 ) (62,299 ) (76,259 ) Net loss (671,720 ) (395,185 ) (2,755,004 ) (3,821,909 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 16,152 16,152 Nine Months Ended September 30, 2019 Diagnostics Therapeutics Corporate Total Royalty revenue $ 13,985 $ — $ — $ 13,985 License revenue 9,953 — — 9,953 Grant and other revenue 309,670 204,919 — 514,589 Total revenue 333,608 204,919 — 538,527 Cost of revenue 6,559 — — 6,559 Research and development expenses 3,194,468 418,315 — 3,612,783 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 15,828 4,985,990 5,001,818 Depreciation and amortization (2) — — 107,794 107,794 Loss from operations (3) (2,867,419 ) (229,224 ) (5,093,784 ) (8,190,427 ) Other income (4) — — 17,456 17,456 Provision for income tax (248 ) (20 ) (439 ) (707 ) Net loss from continuing operations (2,867,667 ) (229,244 ) (5,076,767 ) (8,173,678 ) Loss from discontinued operations, net of tax (2,665 ) — — (2,665 ) Net loss (2,870,332 ) (229,244 ) (5,076,767 ) (8,176,343 ) Total assets, net of depreciation and amortization: United States $ 36,811 $ 93,860 $ 4,688,379 $ 4,819,050 International 2,606 — — 2,606 Capital expenditures — — — — Nine Months Ended September 30, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,842 $ — $ — $ 9,842 License revenue 277,639 — — 277,639 Grant and other revenue 454,830 307,719 — 762,549 Total revenue 742,311 307,719 — 1,050,030 Cost of revenue 73,811 — — 73,811 Research and development expenses 2,409,524 957,920 — 3,367,444 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 45,769 6,095,617 6,141,386 Depreciation and amortization (2) — — 113,088 113,088 Loss from operations (3) (1,741,024 ) (695,970 ) (6,208,705 ) (8,645,699 ) Other expense (4) — — (4,284,014 ) (4,284,014 ) Income tax expense (8,797 ) (3,517 ) (53,017 ) (65,330 ) Net loss from continuing operations (1,749,821 ) (699,487 ) (10,545,736 ) (12,995,043 ) Loss from discontinued operations, net of tax (1,938 ) — — (1,938 ) Gain on sale of discontinued operations, net of tax 43,053 — — 43,053 Net loss (1,708,706 ) (699,487 ) (10,545,736 ) (12,953,928 ) Total assets, net of depreciation and amortization: United States $ 117,722 $ 72,622 $ 8,899,301 $ 9,089,645 International 18,239 — 1,158 19,397 Capital expenditures — — 19,317 19,317

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Apr. 26, 2019$ / sharesshares	Sep. 30, 2019USD ($)$ / sharesshares	Apr. 25, 2019shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001	$ 0.001			$ 0.001
Common Stock, Shares, Outstanding, Ending Balance | shares	10,100,000	18,059,406			10,019,535
Common Stock, Shares Authorized | shares	300,000,000	300,000,000			300,000,000
Notes Payable, Fair Value Disclosure					$ 316,000
Notes Payable, Current, Total		$ 0			316,074
Derivative Liability, Total		63,000			63,000
Operating Lease, Right-of-Use Asset		306,094		$ 406,842
Operating Lease, Liability, Total		$ 824,679		998,602
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset				407,000
Operating Lease, Liability, Total				$ 407,000
Before Reverse Stock Split [Member]
Common Stock, Shares, Outstanding, Ending Balance | shares			201,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Jun. 18, 2019	Dec. 31, 2017	Nov. 30, 2017	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Common Stock				$ 6,046,915	$ 3,000,200
Underwritten Public Offering [Member]
Stock Issued During Period, Shares, New Issues	8,000,000
Shares Issued, Price Per Share	$ 0.75
Proceeds from Issuance of Common Stock	$ 5,555,000
Underwritten Public Offering [Member] | John K. Scott, Jr. [Member]
Stock Issued During Period, Shares, New Issues	4,000,000
Shares Issued, Price Per Share	$ 0.75
Underwritten Public Offering [Member] | Underwriter [Member]
Stock Issued During Period, Shares, New Issues	4,000,000
Shares Issued, Price Per Share	$ 0.69375
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration		$ 4,100,000		$ 4,100,000
Platinum-Montaur Life Sciences LLC Litigation [Member]
Loss Contingency, Damages Sought, Value			$ 1,900,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Contract with Customer, Payment Term, Minimum			15 days
Contract with Customer, Payment Term, Maximum			90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0		$ 0
Revenue from Contract with Customer, Including Assessed Tax	5,000	$ 22,000	35,000	$ 303,000
Contract with Customer, Asset, Impairment Loss	0	0	0	0
Capitalized Contract Cost, Net, Total	0		0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	0		0		$ 12,000
Contract with Customer, Performance Obligation Satisfied in Previous Period	0	0	0	0
Grant [Member]
Revenue Not from Contract with Customer	$ 232,000	$ 169,000	$ 497,000	$ 680,000
INDIA
Contract with Customer, Term of Contract			8 years
CHINA
Contract with Customer, Term of Contract			10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue from contract with customer	$ 5,000	$ 22,000	$ 35,000	$ 303,000
Royalty [Member]
Revenue from contract with customer	4,895	2,382	13,985	9,842
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	4,895	2,382	13,985	9,842
NAV4694 Sublicense [Member] | Diagnostics Segment [Member]
Revenue from contract with customer		14,930		272,639
License [Member]
Revenue from contract with customer		19,930	9,953	277,639
License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer		19,930	9,953	277,639
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer			11,024	15,037
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	$ 4,895	2,382	$ 13,985	9,842
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member] | Diagnostics Segment [Member]
Revenue from contract with customer		$ 5,000		$ 5,000

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Total deferred revenue, beginning of period	$ 1,195,000	$ 721,024	$ 711,024	$ 26,061
Impact of adoption of ASU 2014-09 and related standards				700,000
Revenue deferred related to sublicense			495,000	10,000
Refund of deferred revenue related to sublicense	(495,000)		(495,000)
Revenue recognized from satisfaction of performance obligations		(5,000)	(11,024)	(20,037)
Total deferred revenue, end of period	$ 700,000	$ 716,024	$ 700,000	$ 716,024

Note 4 - Fair Value (Details Te

Note 4 - Fair Value (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Derivative Liability, Total	$ 63,000		$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	$ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	0	0
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	$ 0
Other Liabilities [Member]
Derivative Liability, Total	$ 63,000		$ 63,000

Note 4 - Fair Value - Financial

Note 4 - Fair Value - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)		Sep. 30, 2019	Dec. 31, 2018
Derivative Liability, Total		$ 63,000	$ 63,000
Fair Value, Recurring [Member]
Derivative Liability, Total	[1],[2]	63,000	63,000
Certificates of deposit			799,270
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Derivative Liability, Total	[1],[2]
Certificates of deposit
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Derivative Liability, Total	[1],[2]
Certificates of deposit			799,270
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Derivative Liability, Total	[1],[2]	$ 63,000	63,000
Certificates of deposit
[1]	a. Valuation Processes-Level 3 Measurements: The Company utilizes third-party valuation services that use complex models such as Monte Carlo simulation to estimate the value of our financial liabilities.
[2]	b. Sensitivity Analysis-Level 3 Measurements: Changes in the valuation of MT as a whole may cause material changes in the fair value of the MT warrants. Significant increases (decreases) in the valuation of MT, such as may be the result of additional financing, could result in a higher (lower) fair value measurement. A change in the valuation of MT would not necessarily result in a directionally similar change in the value of the MT warrants.

Note 5 - Stock-based Compensa_3

Note 5 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Expense	$ 50,000	$ 44,000	$ 178,000	$ 261,000
Share-based Payment Arrangement, Expense, Tax Benefit	0	$ 0	0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 83,000		$ 83,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			328 days

Note 5 - Stock-based Compensa_4

Note 5 - Stock-based Compensation - Summary of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Outstanding, January 1, 2019 (in shares) | shares	157,915
Outstanding, January 1, 2019 (in dollars per share) | $ / shares	$ 24.82
Granted (in shares) | shares	95,250
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 5.89
Exercised (in shares) | shares
Exercised, weighted average exercise price (in dollars per share) | $ / shares
Canceled and Forfeited (in shares) | shares	(5,304)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 8.94
Expired (in shares) | shares	(9,041)
Expired, weighted average exercise price (in dollars per share) | $ / shares	$ 31.21
Outstanding, September 30, 2019 (in shares) | shares	238,820
Outstanding, September 30, 2019 (in dollars per share) | $ / shares	$ 17.38
Outstanding, September 30, 2019 (Year)	7 years 146 days
Outstanding, September 30, 2019 | $
Exercisable, September 30, 2019 (in shares) | shares	80,157
Exercisable, September 30, 2019 (in dollars per share) | $ / shares	$ 33.13
Exercisable, September 30, 2019 (Year)	5 years
Exercisable, September 30, 2019 | $

Note 5 - Stock-based Compensa_5

Note 5 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Unvested, January 1, 2019 (in shares) | shares	5,000
Unvested, January 1, 2019 (in dollars per share) | $ / shares	$ 7.42
Granted (in shares) | shares	15,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.75
Vested (in shares) | shares	(5,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 7.42
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested, September 30, 2019 (in shares) | shares	15,000
Unvested, September 30, 2019 (in dollars per share) | $ / shares	$ 2.75

Note 6 - Loss Per Share (Detail

Note 6 - Loss Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,490,531	930,909
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,000	5,000

Note 7 - Investment in Macrop_2

Note 7 - Investment in Macrophage Therapeutics, Inc. (Details Textual)	Aug. 31, 2018
MT [Member] | Dr. Michael Goldberg [Member]
Resignation Agreement, Subidiary Percentage Ownership After Signing	5.00%

Note 8 - Accounts Payable, Ac_2

Note 8 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Director Fees [Member] | Accounts Payable [Member]
Due to Related Parties, Current, Total	$ 65,000
Termination Costs, Bonuses and Director Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 317,000	$ 1,600,000

Note 9 - Notes Payable (Details

Note 9 - Notes Payable (Details Textual) - USD ($)	1 Months Ended			3 Months Ended				9 Months Ended
	Nov. 30, 2018	Nov. 30, 2017	Mar. 31, 2017	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jul. 31, 2012
Gain (Loss) on Extinguishment of Debt, Total									$ (4,265,434)
Interest Expense, Debt, Total				1,000			45,000	6,000	134,000
Notes Payable, Current, Total				0				0		$ 316,074
Interest Expense Compounded				0			$ 44,000	0	129,000
IPFS [Member]
Debt Instrument, Face Amount		$ 396,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues					8,000,000	17,857
Former Chief Executive Officer and President [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues	925,000
Platinum Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity											$ 50,000,000
Interest Expense, Debt, Excluding Amortization								129,000
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member]
Debt Conversion, Original Debt, Amount	$ 2,200,000
Gain (Loss) on Extinguishment of Debt, Total	$ (1,000,000)
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member] | Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	817,857
Debt Conversion, Converted Instrument, Amount	$ 3,200,000
Platinum Loan Agreement [Member] | PPCO [Member]
Repayments of Debt			$ 7,700,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total				$ 0				0		$ 316,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount	$ 393,000
Debt Instrument, Interest Rate, Stated Percentage	5.10%	4.00%
Debt Instrument, Term	300 days	300 days
Debt Instrument, Periodic Payment, Total	$ 40,000	$ 40,000
Interest Expense, Debt, Total								$ 6,000	$ 5,000

Note 10 - Leases (Details Textu

Note 10 - Leases (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2017USD ($)	Sep. 30, 2019USD ($)ft²	Mar. 31, 2019USD ($)ft²	Sep. 30, 2019USD ($)ft²	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Operating Lease, Expense		$ 54,000		$ 176,000
Sublease Income		94,000		283,000
Operating Lease, Right-of-Use Asset		$ 306,094		306,094	$ 406,842
Operating Lease, Payments				$ 249,000
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset					$ 407,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property | ft²		5,000		5,000
Operating Lease, Monthly Base Rent				$ 3,000
Office Space at 560 Sylvan Avenue, Englewood Cliffs, New Jersey [Member]
Area of Real Estate Property | ft²			2,000
Operating Lease, Monthly Base Rent			$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property | ft²		25,000		25,000
Operating Lease, Monthly Base Rent				$ 26,000
Operating Lease, Sublease, Monthly Rent Revenue	$ 39,000
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent				$ 300

Note 10 - Leases - Impact of th

Note 10 - Leases - Impact of the Adoption of ASU 2016-02 on Our Balance Sheet (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease Right-of-use Assets, Pre-adoption balance	$ 306,094	$ 406,842
Operating Lease Liabilities, Pre-adoption balance	$ 824,679	998,602
Terminated Lease Liability, Pre-adoption balance
Deferred Rent, Pre-adoption balance
Previous Accounting Guidance [Member]
Operating Lease Right-of-use Assets, Pre-adoption balance
Operating Lease Liabilities, Pre-adoption balance
Terminated Lease Liability, Pre-adoption balance		589,173
Deferred Rent, Pre-adoption balance		2,587
Adjustments for New Accounting Pronouncement [Member]
Operating Lease Right-of-use Assets, Pre-adoption balance		406,842
Operating Lease Liabilities, Pre-adoption balance		998,602
Terminated Lease Liability, Pre-adoption balance		(589,173)
Deferred Rent, Pre-adoption balance		$ (2,587)

Note 10 - Leases - Amount, Timi

Note 10 - Leases - Amount, Timing and Uncertainty of Cash Flows Arising From Operating Leases (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
2019 (remaining)	$ 90,324
2020	319,034
2021	306,781
2022	253,339
Total undiscounted operating lease payments	969,478
Less imputed interest	144,799
Present value of operating lease liabilities	824,679	$ 998,602
Current lease liabilities	249,615
Noncurrent lease liabilities	$ 575,064
Weighted-average remaining lease term for operating leases (in years) (Year)	2 years 328 days
Weighted-average discount rate for operating leases	12.30%

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)

Apr. 26, 2019

Apr. 18, 2019

Aug. 14, 2018

Apr. 09, 2018USD ($)

Jan. 16, 2018USD ($)

Mar. 03, 2017USD ($)

Nov. 30, 2018shares

Dec. 31, 2017USD ($)

Nov. 30, 2017USD ($)

Jun. 30, 2019shares

Mar. 31, 2019shares

Sep. 30, 2019USD ($)

Dec. 31, 2018USD ($)

Aug. 31, 2018shares

Jun. 30, 2018USD ($)

Stockholders' Equity Attributable to Parent, Ending Balance

$ (761,047)

$ 1,742,139

$ 2,100,000

Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

8,000,000

17,857

Former Chief Executive Officer and President [Member]

Common Stock Shares Provided by Agreement | shares

1,175,000

Common Stock Shares Provided by Agreement, Escrow Period

1 year 180 days

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

925,000

Stock Issued During Period, Shares, New Issues Placed in Escrow | shares

250,000

Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Dr. Michael Goldberg [Member]

Ownership Percentage

5.00%

Maximum [Member] | Reverse Stock Split [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

4,100,000

$ 4,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Term Loan Agreement [Member]

Repayments of Debt

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | CRG [Member] | Term Loan Agreement [Member]

Repayments of Debt

59,000,000

Platinum-Montaur Life Sciences LLC Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Texas Court Judgement Appeal [Member]

Loss Contingency, Damages Sought, Value

$ 4,100,000

CRG [Member] | CRG Loan Agreement, Texas Case [Member] | Minimum [Member]

Litigation Settlement, Amount Awarded to Other Party

$ 66,000,000

CRG [Member] | Global Settlement Agreement [Member] | Maximum [Member]

Litigation Settlement, Amount Awarded to Other Party

$ 66,000,000

Note 12 - Equity (Details Textu

Note 12 - Equity (Details Textual) - USD ($)	Jun. 18, 2019	Mar. 22, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 15, 2019
Stock Issued During Period, Value, New Issues				$ 50,000
Payments of Stock Issuance Costs								$ 572,271
Proceeds from Issuance of Common Stock								$ 6,046,915	$ 3,000,200
Stock Issued During Period, Shares, Issued for Employee Bonuses									55,938
Stock Issued During Period, Value, Issued for Employee Bonuses						$ 151,881	$ 165,021		$ 317,000
Stock Issued During Period, Shares, Employee Benefit Plan								8,128	4,734
Stock Issued During Period, Value, Employee Benefit Plan			$ 19,588				$ 35,980	$ 20,000	$ 36,000
Private Placement [Member]
Stock Issued During Period, Value, New Issues					$ 3,000,000
Private Placement [Member] | Investor [Member]
Stock Issued During Period, Value, New Issues		$ 50,000
Shares Issued, Price Per Share		$ 2.80
Private Placement [Member] | Maximum [Member]
Stock Purchase Agreement, Maximum Value										$ 3,000,000
Underwritten Public Offering [Member]
Stock Issued During Period, Value, New Issues			$ 5,166,441
Shares Issued, Price Per Share	$ 0.75
Stock Issued During Period, Shares, New Issues	8,000,000
Stock Issued, Management Fee, Percentage	1.00%
Proceeds from Issuance of Common Stock	$ 5,555,000
Underwritten Public Offering [Member] | Non-accountable Expenses [Member]
Payments of Stock Issuance Costs	50,000
Underwritten Public Offering [Member] | Fees and Expenses of Legal Counsel [Member]
Payments of Stock Issuance Costs	100,000
Underwritten Public Offering [Member] | Clearing Expenses [Member]
Payments of Stock Issuance Costs	$ 10,000
Underwritten Public Offering [Member] | Offering Investor [Member]
Shares Issued, Price Per Share	$ 0.75
Stock Issued During Period, Shares, New Issues	4,000,000
Underwritten Public Offering [Member] | Underwriter [Member]
Shares Issued, Price Per Share	$ 0.69375
Stock Issued During Period, Shares, New Issues	4,000,000
Over-Allotment Option [Member] | Underwriter [Member]
Shares Issued, Price Per Share	$ 0.69375
Stock Issued During Period, Shares, New Issues	1,200,000

Note 13 - Stock Warrants (Detai

Note 13 - Stock Warrants (Details Textual) - USD ($)	Sep. 30, 2019	Jun. 18, 2019
Class of Warrant or Right, Outstanding	1,400,000
MT [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2,000
Class of Warrant or Right, Outstanding	300
Minimum [Member]
Warrants and Rights Outstanding, Term	30 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.20
Maximum [Member]
Warrants and Rights Outstanding, Term	15 years 328 days
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 50
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 13.46
Underwriting Agreement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		600,000
Class of Warrant or Right Percent of Common Stock Sold		7.50%
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.9375
Class of Warrant or Right, Exercise Price Percent of Share Price	125.00%
Warrants and Rights Outstanding	$ 261,000
Underwriting Agreement Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	88.6
Underwriting Agreement Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	1.8
Underwriting Agreement Warrants [Member] | Measurement Input, Expected Dividend Payment [Member]
Warrants and Rights Outstanding, Measurement Input	0

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	Jan. 01, 2018	Dec. 22, 2017	Sep. 30, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Reclassified to Income Tax Receivable				50.00%
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax				$ 1,200,000
Proceeds from Income Tax Refunds			$ 621,000
Income Taxes Receivable, Noncurrent			621,000
Unrecognized Tax Benefits, Ending Balance			0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total			130,900,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount			8,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total			$ 20,300,000

Note 15 - Segments (Details Tex

Note 15 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Revenues, Total		$ 236,811	$ 231,458	$ 538,527	$ 1,050,030
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 34,289	37,590	$ 107,794	113,088
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 34,289	$ 37,590	107,794	$ 113,088
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($34,289 and $37,590 for the three-month periods ended September 30, 2019 and 2018, and $107,794 and $113,088 for the nine-month periods ended September 30, 2019 and 2018, respectively).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		3 Months Ended						9 Months Ended
		Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Revenue from contract with customer		$ 5,000			$ 22,000			$ 35,000	$ 303,000
Grant and other revenue		231,916			209,146			514,589	762,549
Revenue		236,811			231,458			538,527	1,050,030
Cost of revenue		195			38,101			6,559	73,811
Research and development expenses		1,801,558			1,225,770			3,612,783	3,367,444
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,485,207			2,651,113			5,001,818	6,141,386
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	34,289			37,590			107,794	113,088
(Loss) income from operations (3)	[3]	(3,084,438)			(3,721,116)			(8,190,427)	(8,645,699)
Other income (4)	[4]	10,334			(24,534)			17,456	(4,284,014)
Provision for income taxes					(76,259)			(707)	(65,330)
Net (loss) income		(3,074,104)	$ (2,673,179)	$ (2,429,061)	(3,821,909)	$ (2,394,057)	$ (6,737,962)	(8,176,343)	(12,953,928)
Total assets, net of depreciation and amortization		4,821,656						4,821,656		$ 7,021,527
Capital expenditures					16,152				19,317
Net income (loss)		(3,074,104)	$ (2,673,179)	$ (2,429,061)	(3,821,909)	$ (2,394,057)	$ (6,737,962)	(8,176,343)	(12,953,928)
Net loss from continuing operations								(8,173,678)	(12,995,043)
Loss from discontinued operations, net of tax								(2,665)	(1,938)
Gain on sale of discontinued operations, net of tax									43,053
UNITED STATES
Total assets, net of depreciation and amortization		4,819,050			9,089,645			4,819,050	9,089,645
Non-US [Member]
Total assets, net of depreciation and amortization		2,606			19,397			2,606	19,397
Royalty [Member]
Revenue from contract with customer		4,895			2,382			13,985	9,842
License [Member]
Revenue from contract with customer					19,930			9,953	277,639
Diagnostics Segment [Member]
Grant and other revenue		77,049			65,505			309,670	454,830
Revenue		81,944			87,817			333,608	742,311
Cost of revenue		195			38,101			6,559	73,811
Research and development expenses		1,678,423			711,355			3,194,468	2,409,524
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
(Loss) income from operations (3)	[3]	(1,596,674)			(661,639)			(2,867,419)	(1,741,024)
Other income (4)	[4]
Provision for income taxes		(72)			(10,081)			(248)	(8,797)
Net (loss) income		(1,596,746)			(671,720)			(2,870,332)	(1,708,706)
Capital expenditures
Net income (loss)		(1,596,746)			(671,720)			(2,870,332)	(1,708,706)
Net loss from continuing operations								(2,867,667)	(1,749,821)
Loss from discontinued operations, net of tax								(2,665)	(1,938)
Gain on sale of discontinued operations, net of tax									43,053
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		36,811			117,722			36,811	117,722
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		2,606			18,239			2,606	18,239
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		4,895			2,382			13,985	9,842
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer					19,930			9,953	277,639
Therapeutics Segment [Member]
Grant and other revenue		154,867			143,641			204,919	307,719
Revenue		154,867			143,641			204,919	307,719
Cost of revenue
Research and development expenses		123,135			514,415			418,315	957,920
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,052			20,532			15,828	45,769
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
(Loss) income from operations (3)	[3]	30,680			(391,306)			(229,224)	(695,970)
Other income (4)	[4]
Provision for income taxes		16			(3,879)			(20)	(3,517)
Net (loss) income		30,696			(395,185)			(229,244)	(699,487)
Capital expenditures
Net income (loss)		30,696			(395,185)			(229,244)	(699,487)
Net loss from continuing operations								(229,244)	(699,487)
Loss from discontinued operations, net of tax
Gain on sale of discontinued operations, net of tax
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		93,860			72,622			93,860	72,622
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenue
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,484,155			2,630,581			4,985,990	6,095,617
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	34,289			37,590			107,794	113,088
(Loss) income from operations (3)	[3]	(1,518,444)			(2,668,171)			(5,093,784)	(6,208,705)
Other income (4)	[4]	10,334			(24,534)			17,456	(4,284,014)
Provision for income taxes		55			(62,299)			(439)	(53,017)
Net (loss) income		(1,508,055)			(2,755,004)			(5,076,767)	(10,545,736)
Capital expenditures					16,152				19,317
Net income (loss)		(1,508,055)			(2,755,004)			(5,076,767)	(10,545,736)
Net loss from continuing operations								(5,076,767)	(10,545,736)
Loss from discontinued operations, net of tax
Gain on sale of discontinued operations, net of tax
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		4,688,379			8,899,301			4,688,379	8,899,301
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization					1,158				1,158
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($34,289 and $37,590 for the three-month periods ended September 30, 2019 and 2018, and $107,794 and $113,088 for the nine-month periods ended September 30, 2019 and 2018, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 16 - Supplemental Disclo_2

Note 16 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2019	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Interest Paid, Excluding Capitalized Interest, Operating Activities			$ 6,000	$ 8,000
Stock Issued During Period, Shares, Employee Benefit Plan			8,128	4,734
Stock Issued During Period, Value, Employee Benefit Plan	$ 19,588	$ 35,980	$ 20,000	$ 36,000